Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically Ill and Immunocompromised Patients

Velden, Maikel V. W. van der; Geisberger, Alexander; Dvorak, Thomas; Portsmouth, Daniel; Fritz, Richard; Crowe, Brian A.; Herr, Wolfgang; Distler, Eva; Wagner, Eva; Zeitlinger, Markus; Sauermann, Robert; Stephan, Christoph; Ehrlich, Hartmut J.; Barrett, Perry; Aichinger, Gerald

doi:10.1128/cvi.00065-14

Cited by 12 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such changes result lower protective efficacy of the influenza vaccine, because of mismatch with the circulating strains. Furthermore, the growth of influenza viruses in eggs often conducts some uncertain changes of glycosylation patterns with the original clinical isolates specimen [Ozaki et al, 2004;van der Velden et al, 2014a].…”

Section: Discussionmentioning

confidence: 99%

Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment

Yang

et al. 2016

J. Med. Virol.

View full text Add to dashboard Cite

Usage of influenza vaccine is the best choice measure for preventing and conclusion of influenza virus infection. Although it has been used of chicken embryo to produce influenza vaccine, following with WHO recommended vaccine strain, there were uncontrollable factors and its deficiencies, specially, during an influenza pandemic in the world. The Vero cells are used for vaccine production of a few strains including influenza virus, because of its homology with human, recommended by WHO. However, as known most of the influenza viruses strains could not culture by Vero cells. It was used two high-yield influenza viruses adapted in Vero cells as donor viruses, such as A/Yunnan/1/2005Va (H3N2) and B/Yunnan/2/2005Va (B), to construct high-yield wild influenza virus in Vero cells under antibody selection pressure. After reassortment and passages, it obtained the new Vaccine strains with A/Tianjin/15/2009Va (H1N1), A/Fujian/196/2009Va (H3N2) and B/Chongqing/1384/2010Va (B), which was not only completely keeping their original antigenic (HA and NA), but also grown well in Vero cells with high-yield. All results of gene analysis and HA, HI shown that this reassortment method could be used to find new direction to product the influenza vaccine. J. Med. Virol. 88:1914-1921, 2016. © 2016 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment

Yang

et al. 2016

J. Med. Virol.

View full text Add to dashboard Cite

show abstract

“…A vaccine for seasonal influenza produced in a mammalian cell line, Flucelvax ® , was licensed by the FDA in 2014 [5]. Mammalian cell culture derived H5N1 vaccines have also been shown to be well-tolerated and immunogenic [163][164][165][166]. Other candidates, including an H7N9 vaccine, show promise in preclinical models [167].…”

Section: New Production Methods and Formulationsmentioning

confidence: 99%

Refining the Approach to Vaccines Against Influenza a Viruses with Pandemic Potential

Czakó

Subbarao

2015

Future Virol.

View full text Add to dashboard Cite

Vaccination is the most effective strategy for prevention and control of influenza. Timely production and deployment of seasonal influenza vaccines is based on an understanding of the epidemiology of influenza and on global disease and virologic surveillance. Experience with seasonal influenza vaccines guided the initial development of pandemic influenza vaccines. A large investment in pandemic influenza vaccines in the last decade has resulted in much progress and a body of information that can now be applied to refine the established paradigm. Critical and complementary considerations for pandemic influenza vaccines include improved assessment of the pandemic potential of animal influenza viruses, proactive development and deployment of pandemic influenza vaccines, and application of novel platforms and strategies for vaccine production and administration.

show abstract

“…Blood was drawn immediately before and 21 days after each vaccination. Neuraminidase-inhibiting antibody titers were determined for all serum samples that were available after the original immunogenicity evaluation [ 3 ] from participants with at least 1 pre- and postvaccination study site visit. Written informed consent was obtained for all participants before enrollment.…”

Section: Methodsmentioning

confidence: 99%

“…However, in the event of a pandemic, the highest rates of severe disease complications can be expected in individuals with immunodeficiencies or chronic illness, who qualify for prioritized vaccination. The effectiveness of a cell culture-derived whole-virus H5N1 vaccine to induce hemagglutinin (HA)-specific antibodies, which provide protective immunity by preventing virus attachment to the host cell or endosomal membrane fusion, has recently been demonstrated in these special populations [ 3 ]. Because immune dysfunction might compromise vaccine responses, it is especially important to investigate the full breadth of antibodies induced by a pandemic influenza vaccine in these risk groups.…”

mentioning

confidence: 99%

Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients

Fritz¹,

Hetzelt²,

Ilk

et al. 2014

Open Forum Infectious Diseases

Self Cite

View full text Add to dashboard Cite

Neuraminidase-inhibiting (NAi) antibodies have been reported to be an independent correlate of protection from influenza disease, but the NAi antibody response to influenza vaccination has never been assessed in chronically ill or immunocompromised participants. Using an enzyme-linked lectin assay, we demonstrated that 2 immunizations with a Vero cell culture-derived, whole-virus H5N1 A/Vietnam vaccine induces NAi antibodies in 94.3% of chronically ill and 83.8% of immunocompromised participants. A booster with a heterologous A/Indonesia H5N1 vaccine induced comparable NAi antibody titers in both groups and resulted in 100% seropositivity. These data support prepandemic H5N1 vaccination strategies for these highly vulnerable risk groups.

show abstract

Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically Ill and Immunocompromised Patients

Cited by 12 publications

References 30 publications

Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment

Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment

Refining the Approach to Vaccines Against Influenza a Viruses with Pandemic Potential

Neuraminidase-Inhibiting Antibody Response to H5N1 Virus Vaccination in Chronically Ill and Immunocompromised Patients

Contact Info

Product

Resources

About